Prescription medication · Mu-Opioid Receptor Agonist (IBS-D)
eluxadoline
Also sold as Viberzi. Viberzi is used to treat irritable bowel syndrome with diarrhea, also known as IBS-D, in adults.
Data updated 2026-05-15
- 2,870
- FDA reportsLightly reported
- 6
- InteractionsFew interactions
- $25.60
- Brand price (NADAC)
What the data shows
eluxadoline (Viberzi) is a prescription Mu-Opioid Receptor Agonist (IBS-D), among the least-reported drugs the FDA tracks (2,870 FDA reports), with 6 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
eluxadoline (Viberzi) is a prescription Mu-Opioid Receptor Agonist (IBS-D). Viberzi is used to treat irritable bowel syndrome with diarrhea, also known as IBS-D, in adults.
Viberzi is a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. It helps to reduce diarrhea associated with IBS-D.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$25.60/unit
Generic Available
No
ABBVIE
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Viberzi is used to treat irritable bowel syndrome with diarrhea, also known as IBS-D, in adults.
Common side effects
Constipation, Nausea, Abdominal pain
Key warnings
Viberzi can cause serious side effects, including pancreatitis and sphincter of Oddi spasm.
The sections below are summarized in plain English from eluxadoline's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Viberzi works by acting on opioid receptors in your gut. It slows down bowel movements. This helps to reduce diarrhea and abdominal pain.
How to Take It
Take Viberzi twice a day with food. The usual dose is 100 mg twice daily. Your doctor may prescribe a lower dose of 75 mg twice daily if you have certain health conditions or are taking other medicines. If you miss a dose, take your next dose at the regular time.
This is a plain-language summary of eluxadoline's FDA labeling, not individualized dosing advice. Ask a pharmacist or prescriber before changing how you take this medication.
Pregnancy & Breastfeeding
It is not known if Viberzi can harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Viberzi passes into breast milk. Talk to your doctor about the best way to feed your baby if you take Viberzi.
This is a plain-language summary of eluxadoline's FDA labeling, not individualized advice. Ask a pharmacist or prescriber about pregnancy or breastfeeding on this medication.
Missed Dose
If you miss a dose of Viberzi, take your next dose at the regular time. Do not take two doses at the same time to make up for the missed dose.
This is a plain-language summary of eluxadoline's FDA labeling, not individualized advice. Ask a pharmacist or prescriber what to do about your specific missed dose.
Storage
Store Viberzi tablets at room temperature, between 68°F and 77°F.
Side Effects (from patient reports)
Based on 2,870 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for eluxadoline, by number of reports
- Stomach pain
Stomach pain
348 reports
- Diarrhea
Diarrhea
340 reports
- Constipation
Constipation
281 reports
- Inflammation of the pancreas
Inflammation of the pancreas
276 reports
- Feeling sick to your stomach
Feeling sick to your stomach
216 reports
- Pain in the upper stomach
Pain in the upper stomach
207 reports
- Taking the medicine at the wrong times
Taking the medicine at the wrong times
162 reports
- Throwing up 135
Throwing up
135 reports
- Feeling tired 118
Feeling tired
118 reports
- Feeling lightheaded 108
Feeling lightheaded
108 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for eluxadoline each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where eluxadoline sits
eluxadoline has more FDA adverse-event reports than 17% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is eluxadoline; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 2,870 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2012–2025.
Total Reports
2,870
Reports Mentioning Death
63
2.2% of reports — not proof of cause
Hospitalization Reports
546
Top Indication
Irritable Bowel Syndrome
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 2 | ABDOMINAL PAIN | 348 |
| 3 | DIARRHOEA | 340 |
| 4 | CONSTIPATION | 281 |
| 5 | PANCREATITIS | 276 |
| 6 | NAUSEA | 216 |
| 8 | ABDOMINAL PAIN UPPER | 207 |
| 9 | INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION | 162 |
| 10 | VOMITING | 135 |
| 11 | FATIGUE | 118 |
| 12 | DIZZINESS | 108 |
| 14 | PAIN | 103 |
| 15 | INCORRECT DOSE ADMINISTERED | 88 |
| 16 | FEELING ABNORMAL | 83 |
| 17 | SPHINCTER OF ODDI DYSFUNCTION | 83 |
| 18 | PANCREATITIS ACUTE | 77 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Viberzi can cause serious side effects, including pancreatitis and sphincter of Oddi spasm. These conditions can cause severe abdominal pain, nausea, and vomiting. If you have new or worsening abdominal pain, stop taking Viberzi and get medical help right away. Do not take Viberzi if you do not have a gallbladder.
Known Drug Interactions
Increased exposure to rosuvastatin when co-administered with VIBERZI with a potential for increased risk of myopathy/rhabdomyolysis [ see Clinical Pharmacology ( 12.3 ) ] Intervention: Use the lowest effective dose of rosuvastatin (see prescribing information of rosuvastatin for additional information on recommended dosing).
Mechanism: Eluxadoline can increase the amount of rosuvastatin in your blood, which may lead to a higher risk of muscle damage.
What to do: Use the lowest effective dose of rosuvastatin and watch for any muscle pain or weakness.
Examples: cyclosporine, gemfibrozil, antiretrovirals (atazanavir, lopinavir, ritonavir, saquinavir, tipranavir), rifampin, eltrombopag Drugs that Cause Constipation Clinical Impact: Increased risk for constipation related adverse reactions and potential for constipation related serious adverse reactions Intervention: Avoid use with other drugs that may cause constipation (see below); loperamide may be used occasionally for acute management of severe diarrhea but avoid chronic use.
Mechanism: Both of these medications can slow down your digestive tract, which increases the risk of severe constipation.
What to do: Avoid taking these two drugs together to prevent serious constipation problems.
Examples: cyclosporine, gemfibrozil, antiretrovirals (atazanavir, lopinavir, ritonavir, saquinavir, tipranavir), rifampin, eltrombopag Drugs that Cause Constipation Clinical Impact: Increased risk for constipation related adverse reactions and potential for constipation related serious adverse reactions Intervention: Avoid use with other drugs that may cause constipation (see below); loperamide may be used occasionally for acute management of severe diarrhea but avoid chronic use. Discontinue loperamide immediately if constipation occurs.
Mechanism: These medicines both work to slow down your bowels, and using them together can cause dangerous levels of constipation.
What to do: Do not use loperamide long-term with this drug, and stop it immediately if you become constipated.
Examples: cyclosporine, gemfibrozil, antiretrovirals (atazanavir, lopinavir, ritonavir, saquinavir, tipranavir), rifampin, eltrombopag Drugs that Cause Constipation Clinical Impact: Increased risk for constipation related adverse reactions and potential for constipation related serious adverse reactions Intervention: Avoid use with other drugs that may cause constipation (see below); loperamide may be used occasionally for acute management of severe diarrhea but avoid chronic use.
Mechanism: Both drugs can cause constipation as a side effect, making it much more likely to happen if they are taken at the same time.
What to do: Avoid using these medications together to reduce the risk of serious bowel issues.
Table 2: Established and Other Potentially Clinically Relevant Interactions Affecting VIBERZI OATP1B1 Inhibitors Clinical Impact: Increased exposure to eluxadoline when coadministered with cyclosporine [ see Clinical Pharmacology ( 12.3 ) ] Intervention: Administer VIBERZI at a dose of 75 mg twice daily [see Dosage and Administration ( 2 )] and monitor patients for impaired mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery and for other eluxadoline-related adverse reactions [see Adverse Reactions ( 6.1 )] ....
Mechanism: Cyclosporine blocks a specific protein that helps remove eluxadoline from your system, which causes eluxadoline levels to rise in your body.
What to do: Your doctor should lower your eluxadoline dose to 75 mg twice daily and monitor you for side effects like extreme tiredness or trouble driving.
This is a plain-language summary of interactions documented in FDA labeling, not individualized advice. Ask a pharmacist or prescriber before combining medications.
Common Questions
What is Viberzi used for?
How should I take Viberzi?
What should I do if I miss a dose?
What are the common side effects of Viberzi?
Can Viberzi cause serious side effects?
Can I drink alcohol while taking Viberzi?
Can I take Viberzi if I don't have a gallbladder?
What should I do if I develop severe constipation?
Is Viberzi safe to take during pregnancy?
How should I store Viberzi?
What are the common side effects of eluxadoline?
Does eluxadoline interact with other medications?
What drug class is eluxadoline?
Is eluxadoline safe during pregnancy?
Related Medications in Mu-Opioid Receptor Agonist (IBS-D)
Other drugs grouped near eluxadoline - same-class peers and common alternatives.
alosetron
Lotronex
Alosetron (Lotronex) is a medicine for women with severe diarrhea-predominant irritable bowel syndrome (IBS).
Compare with eluxadoline →
aprepitant
Emend
Aprepitant (Emend) is a medicine that helps prevent nausea and vomiting.
Compare with eluxadoline →
bisacodyl
Dulcolax
Bisacodyl is a medicine that helps you have a bowel movement.
Compare with eluxadoline →
bismuth subsalicylate
Pepto-Bismol
Bismuth subsalicylate (Pepto-Bismol) is a medicine that can treat diarrhea and upset stomach.
Compare with eluxadoline →
cimetidine
Tagamet
Cimetidine (Tagamet) reduces stomach acid.
Compare with eluxadoline →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
Why some drugs demand precise dosing and monitoring
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on eluxadoline
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for eluxadoline
The FDA label for eluxadoline (sold under brand names such as Viberzi) classifies it as a prescription-only medication in the Mu-Opioid Receptor Agonist (IBS-D) class. Viberzi is used to treat irritable bowel syndrome with diarrhea, also known as IBS-D, in adults. Official labeling lists 3 commonly reported side effects, including Constipation, Nausea, Abdominal pain.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 2,870 voluntary reports. The database also lists 6 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice, always consult a licensed healthcare provider before starting, stopping, or changing any medication.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.
Last updated: July 16, 2024
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled and last refreshed May 2026. See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages